Image Credit: heitipaves/123rf.com
Immunotherapy has significantly transformed cancer treatment over the last decade, but prostate cancer has remained largely unresponsive to these advancements. Researchers have long categorized prostate cancer as “immune-cold,” indicating a lack of immune system recognition and response. However, recent developments involving a new drug, VIR-5500, show promise in changing this narrative.
In an early-stage clinical trial, 58 men with advanced prostate cancer who had not responded to existing treatments were administered VIR-5500, an engineered antibody developed by Vir Biotechnology. Preliminary results presented at the American Society of Clinical Oncology genitourinary cancers symposium in San Francisco reveal noteworthy outcomes, although the findings have yet to undergo peer review.
Among participants receiving the highest dose, 82 percent experienced a reduction in prostate-specific antigen (PSA) levels by at least half, a key marker used to monitor disease activity. Notably, 53 percent had PSA levels drop by at least 90 percent, while 29 percent saw reductions of 99 percent or more. Additionally, among 11 patients with measurable tumors at the highest dose, five exhibited tumor shrinkage. One remarkable case involved a 63-year-old man whose cancer had metastasized to his liver; after six treatment cycles, all 14 cancerous lesions resolved entirely. The treatment was well-tolerated, with 88 percent of participants reporting only mild side effects.
VIR-5500 functions as a T-cell engager, facilitating the interaction between the immune system’s killer T-cells and tumor cells that typically evade immune detection. Unlike other drugs in this class that have caused severe inflammatory responses, VIR-5500 is designed to activate solely within the tumor microenvironment. This specificity minimizes side effects and allows the drug to remain in the bloodstream longer, potentially reducing the frequency of required doses.
Experts are optimistic about the implications of these findings. The potential of VIR-5500 represents a new class of treatment for prostate cancer, which has desperately needed innovative solutions, given the high mortality rates associated with the disease. Plans for further clinical trials are underway to explore the efficacy of this treatment on a larger scale. Although these findings are preliminary and not yet validated through peer review, the observed tumor shrinkage and resolution of lesions mark a significant breakthrough in the fight against prostate cancer.
Check out the original article here: Source link
